{
    "patient": {
        "Name": "Alexandra Oconnor",
        "DateOfBirth": "1968-03-09",
        "Sex": "Female",
        "Diagnosis": "Adenocarcinoma",
        "BodyPart": "Lung",
        "Physician": "Dr. Duane Adams",
        "TreatingInstitution": "Winters LLC"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Lung",
            "CollectedDate": "2023-05-01",
            "ReceivedDate": "2023-05-01",
            "TumorPercentage": "30%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-05-02",
            "ReceivedDate": "2023-05-09"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "SMO",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A374E Stopgain-LOF",
                "VariantAlleleFraction": "39.39%"
            },
            {
                "Gene": "HDAC1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.Y303H Frameshift-LOF",
                "VariantAlleleFraction": "28.89%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "U2AF1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R156X Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "27.05%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "HDAC2",
            "PKLR",
            "SDHA",
            "PTEN",
            "ABL1"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "24 m/Mb",
            "Tmbpercentile": "92%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "High"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "IKZF1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.N159Y Nonsense-GOF",
                "VariantAlleleFraction": "13.64%"
            },
            {
                "Gene": "RNF43",
                "DNA Alteration": "c.954G>T",
                "GeneMutation": "p.A169T Nonsense-LOF",
                "VariantAlleleFraction": "17.84%"
            },
            {
                "Gene": "CHD6",
                "DNA Alteration": "c.4800C>G",
                "GeneMutation": "p.I1600M Nonsense-GOF",
                "VariantAlleleFraction": "9.95%"
            },
            {
                "Gene": "IKZF1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.N159Y Nonsense-LOF",
                "VariantAlleleFraction": "1.41%"
            },
            {
                "Gene": "HSD3B1",
                "DNA Alteration": "c.1100C>A",
                "GeneMutation": "p.T367= Frameshift-GOF",
                "VariantAlleleFraction": "2.03%"
            },
            {
                "Gene": "MAP2K2",
                "DNA Alteration": "c.383C>T",
                "GeneMutation": "p.P128L Nonsense-LOF",
                "VariantAlleleFraction": "4.35%"
            },
            {
                "Gene": "GNAS",
                "DNA Alteration": "c.374A>G",
                "GeneMutation": "p.R201S Nonsense-LOF",
                "VariantAlleleFraction": "9.04%"
            },
            {
                "Gene": "MYO1G",
                "DNA Alteration": "c.145G>A",
                "GeneMutation": "p.V49M Frameshift-GOF",
                "VariantAlleleFraction": "9.62%"
            }
        ],
        "Germline": [
            {
                "Gene": "CTNNB1",
                "DNA Alteration": "c.97T>C",
                "GeneMutation": "p.S45P Stopgain-LOF",
                "Condition": "technology"
            },
            {
                "Gene": "TP53",
                "DNA Alteration": "c.638G>A",
                "GeneMutation": "p.V272A Nonsense-LOF",
                "Condition": "rise"
            }
        ]
    },
    "low coverage regions": [
        "CSF3R",
        "BRCA2",
        "ARID2"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "SMO",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A374E Stopgain-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "39.39%"
            },
            {
                "Gene": "HDAC1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.Y303H Frameshift-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "28.89%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "U2AF1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R156X Missensevariant(exon2)-GOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "27.05%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-04-30"
    },
    "other": {
        "ReportId": "1918",
        "ReportDate": "2023-05-04",
        "SignedBy": "Duane Adams",
        "Supervisor": "Dr. Jason Rojas"
    }
}